- Call her savvy? Harris unleashes unconventional media blitz
- Lucian Freud 'masterpiece' fetches £13.9 million at London sale
- SoFi Stadium to hold next two CONCACAF Nations League finals
- McIlroy and DeChambeau set for PGA-LIV 'Showdown' in Vegas
- Fed minutes highlight divisions over rate cut decision
- Steve McQueen debuts new WWII film at London festival
- Run blitz edges India and South Africa closer to World Cup semi-finals
- Zelensky to court European leaders in drive for military aid
- Israel captain says 'difficult' to focus on football in time of war
- Macron to host Ukraine's Zelensky after meeting Ukrainian troops
- Root says 'many more to get' after England Test runs landmark
- India pile up World Cup high to rout Sri Lanka
- One year later, Israeli hostage family learns of loss
- Texans receiver Collins, Pats' safety Peppers out for NFL clash
- Biden-Netanyahu talk as Hezbollah, Israeli forces clash
- Musk's X available again in Brazil after 40-day ban
- Reddy stars as India crush Bangladesh to clinch T20 series
- Nobel winners hope protein work will spur 'incredible' breakthroughs
- What are proteins again? Nobel-winning chemistry explained
- Arch rivals Ghana, Nigeria drawn together in CHAN qualifying
- AI steps into science limelight with Nobel wins
- Trump lauds India's Modi as 'total killer'
- Wall Street, Europe rise as Chinese shares tumble
- Hunkering down for Hurricane Milton at Disney -- but first, a few rides
- Reddy, Rinku power India to 221-9 in second Bangladesh T20
- Overshooting 1.5C risks 'irreversible' climate impact: study
- Time running out in Florida to flee Hurricane Milton
- Demis Hassabis, from chess prodigy to Nobel-winning AI pioneer
- The long walk for water in the parched Colombian Amazon
- Biden-Netanyahu to talk as Hezbollah, Israeli forces clash
- France vows to step up drugs fight after police vehicles torched
- Air France says jet flew over Iraq during Iran attack on Israel
- Activists target Picasso work to protest Israel arms sales
- Let 'Emily in Paris' remain in Paris, Macron says
- Global stocks diverge as Chinese shares tumble
- Time runs out in Florida to flee Hurricane Milton
- Chad issues warning ahead of more devastating floods
- Record-breaking Root helps England dominate Pakistan in first Test
- German govt sees economy shrinking again in 2024
- Ex-UK soldier denies passing secrets to Iran intelligence
- Creator's death no bar to new 'Dragon Ball' products
- Three Kosovo Serbs on trial over 'secession plot' attack
- Van Gogh museum to launch Impressionism show
- French minister ups ante in Eiffel Tower Olympic rings row
- Japan PM calls snap election to 'create a new Japan'
- German police shut pro-Palestinian camp over Thunberg invite
- Chinese stocks tumble on lack of fresh stimulus
- Trio wins chemistry Nobel for protein design, prediction
- SE Asian summit urges end to Myanmar violence but struggles for solutions
- Wimbledon replaces line judges with electronic system
RBGPF | -2.48% | 59.33 | $ | |
RYCEF | -1.01% | 6.9 | $ | |
CMSD | -0.17% | 24.81 | $ | |
RIO | -0.54% | 66.3 | $ | |
CMSC | 0.04% | 24.65 | $ | |
VOD | 0.77% | 9.735 | $ | |
SCS | 1.92% | 13.03 | $ | |
NGG | -0.33% | 65.685 | $ | |
JRI | 0.34% | 13.205 | $ | |
BCC | 0.45% | 142.66 | $ | |
RELX | 0.28% | 46.77 | $ | |
BCE | -0.52% | 33.337 | $ | |
BTI | 0.71% | 35.472 | $ | |
GSK | 5.82% | 40.37 | $ | |
AZN | 0.82% | 77.505 | $ | |
BP | 0.02% | 32.035 | $ |
US approves Moderna's RSV vaccine for older adults
The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- marking the first time any mRNA shot has been authorized against a disease other than Covid-19.
RSV is a highly contagious seasonal virus that can cause severe symptoms in infants and the elderly that causes around 60,000–160,000 hospitalizations and 6,000–10,000 deaths per year in the United States, according to official estimates.
There are already two approved vaccines for those aged 60 and over, by GSK and Pfizer, both of which have been on the market since last year.
"The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform," said Stephane Bancel, chief executive officer of the US biotech firm, in a statement.
"mRESVIA protects older adults from the severe outcomes of RSV infection," he continued, adding that unlike its competitors, Moderna's shot was available in pre-filled syringes to reduce the risk of clinical errors.
GSK and Pfizer's vaccines rely on traditional recombinant protein technology, introducing a pathogen component to the immune system to trigger a response.
In contrast, Moderna's vaccine utilizes cutting-edge messenger RNA (mRNA) technology, instructing the body to produce a unique protein that stimulates an immune response, teaching it to defend against the infection.
The approval was based on positive trial data published in the New England Journal of Medicine in December.
A global study of approximately 37,000 people aged 60 and older found the shot had an efficacy of 83.7 percent against lower respiratory tract disease -- meaning when an RSV becomes more severe and can cause pneumonia, bronchitis, shortness of breath and more.
There were no serious safety concerns, with common side effects including pain at the injection site, fatigue, headache, body aches and joint stiffness.
Moderna said it expected the vaccines to be available for the 2024-2025 RSV season, and had filed for approval with regulators around the world.
A.Mahlangu--AMWN